Prof Yasuhisa Fujii is an expert in Urology at Tokyo Medical and Dental University (Japan). As of November 2026, ScienceLeadR ranks Yasuhisa Fujii in the top 1% of experts worldwide for Urologic Neoplasms, Kidney Neoplasms and Urinary Bladder Diseases. Yasuhisa Fujii has authored 799 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 3,186 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Yasuhisa Fujii Tokyo Medical and Dental University Japan
3 186 ScienceLeadR Reputation 3186
Network Map

Urology

Subspecialties: Oncology - Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Tokyo Medical and Dental University

2003 - 2026

Tokyo Metropolitan Institute of Medical Science

2024 - 2026

Tokyo University of Science

2025 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 799

Citations

Citations: 12 459 1st author: 17 Last author: 328 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Editorial Comment to Interpreting International Real-World Survival Outcomes After Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data.
PMID 43053174 — maintenance
Int J Urol20260
A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.
PMID 42632050 — urinary bladder neoplasms, treatment outcome, neoplasms, survival analysis, proportional hazards models, therapeutics
Jpn J Clin Oncol20260
Machine learning models to predict pathological complete response after chemoradiotherapy in muscle-invasive bladder cancer: toward optimized indications for bladder preservation.
PMID 42997524 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, machine learning, cystectomy, chemoradiotherapy, learning
Clin Transl Radiat Oncol20260
Sensitivity of mHSPC Overall Survival Network Estimates to the Historical Docetaxel Bridge.
PMID 42978053 — docetaxel, urologic diseases, survival analysis, prostatic neoplasms
Int J Urol20260
Prolonged and Nocturnal Hypoglycemia Following Resection of Pheochromocytoma and Paraganglioma: A Prospective Study Using Intermittent-Scanning Continuous Glucose Monitoring.
PMID 42972661 — paraganglioma, blood glucose, insulin, blood, pheochromocytoma, urologic diseases, sex, hypoglycemia, prospective studies, continuous glucose monitoring
Int J Urol20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7

By status:

Completed 4
Active not recruiting 3

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK 3475) Versus Neoadjuvant Chemotherapy for Cisplatin Eligible Muscle Invasive Bladder Cancer (MIBC) (MK 3475 B15 KEYNOTE B15 EV 304)
NCT04700124 — urinary bladder, urinary bladder neoplasms, cells, b7-h1 antigen, lewy bodies, muscles, lymph nodes, parkinson disease, surgical procedures, operative, neoplasms, duration of therapy, drug therapy, cystectomy, lymph, therapeutics, random allocation, ligands, cell death, dissection, chemotherapy
Phase 3Active not recruiting2021
A Study of Belzutifan (MK 6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK 6482 011)
NCT04586231 — cells, administration, oral, carcinoma, renal cell, therapeutics, carcinoma
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map